Aikaterini Vassilakos Selected Research

Neoplasms (Cancer)

7/2011	Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
1/2009	GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
4/2007	RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
5/2006	Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
2/2006	GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
2/2006	Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin.
2/2004	NC381, a novel anticancer agent, arrests the cell cycle in G0-G1 and inhibits lung tumor cell growth in vitro and in vivo.
1/2004	Triaryl methane derivatives as antiproliferative agents.
6/2003	GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aikaterini Vassilakos Research Topics

Disease

9	Neoplasms (Cancer) 07/2011 - 06/2003
3	Neoplasm Metastasis (Metastasis) 04/2007 - 06/2003
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2009 - 06/2003
2	Breast Neoplasms (Breast Cancer) 05/2006 - 06/2003
2	Melanoma (Melanoma, Malignant) 02/2006 - 06/2003
2	Astrocytoma (Pilocytic Astrocytoma) 02/2006 - 06/2003
2	Lymphoma (Lymphomas) 02/2006 - 06/2003
2	Glioblastoma (Glioblastoma Multiforme) 02/2006 - 06/2003
1	Colonic Neoplasms (Colon Cancer) 10/2003
1	Adenocarcinoma 06/2003
1	Burkitt Lymphoma (Burkitt's Lymphoma) 06/2003

Drug/Important Bio-Agent (IBA)

5	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2009 - 06/2003
4	GTI2040IBA 07/2011 - 06/2003
2	Antisense OligonucleotidesIBA 01/2009 - 02/2006
2	Messenger RNA (mRNA)IBA 05/2006 - 02/2006
2	imidazoleIBA 02/2004 - 01/2004
2	Antineoplastic Agents (Antineoplastics)IBA 02/2004 - 06/2003
2	Clotrimazole (Lotrimin)FDA LinkGeneric 02/2004 - 01/2004
1	Interferon-alpha (Interferon Alfa)IBA 01/2009
1	Small Interfering RNA (siRNA)IBA 04/2007
1	Capecitabine (Xeloda)FDA Link 05/2006
1	ribonucleotide reductase M2IBA 05/2006
1	Transcription Factors (Transcription Factor)IBA 02/2006
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2006
1	Proteins (Proteins, Gene)FDA Link 02/2006
1	GTI2501IBA 02/2006
1	ThioredoxinsIBA 02/2006
1	OligonucleotidesIBA 06/2003